faropenem

Faropenem, a highly efficacious and orally bioavailable beta-lactam antibiotic, exhibits an extensive range of in vitro antimicrobial activity against diverse gram-positive and -negative aerobes and anaerobes. Notably, Faropenem possesses inherent resistance to hydrolysis by virtually all beta-lactamases, including extended-spectrum beta-lactamases and AmpC beta-lactamases. Moreover, Faropenem has been developed as an oral prodrug, namely faropenem medoxomil, for the investigation of respiratory tract infections.

Faropenem sodium is an orally bioavailable penem antibiotic effective in treating Mycobacterium tuberculosis, as well as tuberculosis and community-acquired pneumonia.

Faropenem daloxate (Faropenem medoxil) is useful for penem and antibiotics. Faropenem medoxomil has excellent in vitro activity against Streptococcus pneumoniae, Haemophilus influenzae and other key pathogens implicated in acute bacterial rhinosinusitis.Faropenem daloxate is the first oral penem in a new class of beta-lactam antibiotics.

Faropenem sodium hemipentahydrate is an orally administered beta-lactam antibiotic within the penem group, exhibiting resistance to certain types of extended-spectrum beta-lactamase (beta-lactamase).

Faropenem-d7 Sodium Salt is a deuterated compound of Faropenem Sodium Salt. Faropenem Sodium Salt has a CAS number of 122547-49-3. Faropenem sodium is an orally bioavailable penem antibiotic which can efficiently kill Mycobacterium tuberculosis.It treatment of tuberculosis and community-acquired pneumonia.